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Abstract: In recent decades, important advances have been made in the diagnosis and 
treatment of invasive aspergillosis (IA) and mucormycosis. One of these advances has been the 
introduction of isavuconazole, a second-generation broad spectrum triazole with a favorable 
pharmacokinetic and safety profile and few drug–drug interactions. Phase III trials in patients 
with IA and mucormycosis demonstrated that isavuconazole has similar efficacy to voricon-
azole for the treatment of IA (SECURE trial) and liposomal amphotericin B for the treatment 
of mucormycosis (VITAL trial with subsequent case–control analysis) and a favorable safety 
profile with significantly fewer ocular, hepatobiliary, and skin and soft tissue adverse events 
compared to voriconazole. As a result, recent IA guidelines recommend isavuconazole (together 
with voriconazole) as gold standard treatment for IA in patients with underlying hematological 
malignancies. In contrast to liposomal amphotericin B, isavuconazole can be safely administered 
in patients with reduced renal function and is frequently used for the treatment of mucormycosis 
in patients with reduced renal function. Updated guidelines on mucormycosis are needed to 
reflect the current evidence and give guidance on the use of isavuconazole for mucormycosis. 
Studies are needed to evaluate the role of isavuconazole for 1) anti-mold prophylaxis in high-
risk patients, 2) salvage treatment for IA and mucormycosis, and 3) treatment for other mold 
infections such as Scedosporium apiospermum.
Keywords: TDM, plasma level, triazole, SECURE, VITAL, susceptibility, real life
Introduction
In recent decades, important advances have been made in the diagnosis of invasive 
aspergillosis (IA) and mucormycosis,1–8 although IA and mucormycosis still remain 
difficult to diagnose.9 In order to improve survival, empiric antifungal treatment is 
frequently initiated at early stages of infection where IA and/or mucormycosis are 
suspected, but mycological evidence is still missing.10
The introduction of broad spectrum antifungal agents such as voriconazole, posacon-
azole, and lipid-based formulations of amphotericin B has substantially improved the 
survival rates in patients with IA and mucormycosis over the past 15 years.11–14 Despite 
the overall improved safety profiles that came with these new treatment options, treatment 
of IA and mucormycosis remains complex due to unpredictable pharmacokinetic profiles, 
requiring therapeutic drug monitoring (TDM) for optimization of efficacy and prevention 
of adverse effects and multiple drug–drug interactions through the cytochrome P450 
system.10,15–19 The recent introduction of isavuconazole, a new potent second-generation 
triazole with a favorable pharmacokinetic and safety profile, let to a reduction in drug–
drug interactions. Similar efficacy of isavuconazole compared to other triazoles, may 
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simplify treatment, and improve clinical practice. This review 
discusses the pharmacology of isavuconazole as well as its 
efficacy for the treatment of IA and mucormycosis in animal 
models, clinical studies, and real-life settings. We further dis-
cuss the prominent role of isavuconazole in recent guidelines 
and address future research questions.
Pharmacology
Chemistry and pharmacokinetics
The prodrug of isavuconazole, isavuconazonium sulfate, is 
a water-soluble triazole precursor that can be administered 
both orally and intravenously. After administration, isavu-
conazonium sulfate is broken down by plasma esterases to the 
active component, isavuconazole, and an inactive cleavage 
product. This conversion occurs rapidly, with a half-life of 
less than a minute in vitro20,21 and with no detectable levels 
of prodrug or cleavage products following intravenous (IV) 
infusion after 30 minutes in healthy adults.22
Isavuconazole disrupts ergosterol biosynthesis by inhib-
iting cytochrome P450-dependent 14α-lanosterol dem-
ethylation, an essential component of ergosterol production. 
This mechanism is similar to that of the other azoles and 
significantly alters the structure and function of the fungal 
membrane, leading to cell death.20,21 In addition, isavucon-
azole consists of an [N-(3-acetoxypropyl)-N-methylamino]-
carboxymethyl group side arm that orients the molecule to 
engage the triazole ring to the binding pocket of the fungal 
CYP51 protein, conferring activity against some pathogens 
resistant to other azoles, including itraconazole, voriconazole, 
and posaconazole.23
Unlike the other second-generation triazoles, isavucon-
azole is highly water soluble and does not require the addi-
tion of a beta-cyclodextrin to its IV formulation to facilitate 
solubility,24 eliminating the potential for nephrotoxicity from 
the cyclodextrin vehicle. Isavuconazole has a large volume 
of distribution and is highly protein bound with ~98% bound 
to proteins, mostly to albumin.23 The absorption and serum 
concentrations of isavuconazole are not dependent on the 
timing of food intake, so it can be taken with or without 
food.25 The serum concentrations of isavuconazole are not 
reduced in patients with mucositis,26 and the bioavailability 
is not affected with concomitant administration of medica-
tions that suppress gastric acid production, so it can be taken 
with proton pump inhibitors or other medications that affect 
gastric acid secretion.27
Key pharmacokinetic characteristics of isavuconazole 
are displayed in Table 1. Conventional dosing is expressed 
in terms of milligram equivalent of the active compound, 
isavuconazole. The recommended dose for both oral and IV 
administration is a loading dose of 200 mg of isavuconazole 
(equivalent to 372 mg of isavuconazonium sulfate) every 
8 hours for six doses given over a 48-hour period, followed 
by a maintenance dose of 200 mg of isavuconazole daily.
In healthy adult volunteers, isavuconazole demonstrates 
dose-proportional pharmacokinetics with low inter-subject 
and intra-subject variabilities. However, high body mass 
index has been shown to be associated with higher clearance 
of isavuconazole.28 The bioavailability of isavuconazole is 
excellent with ~98% of the active drug reaching circulation. 
In healthy volunteers, plasma concentrations reached a maxi-
mum concentration after 2–3 hours of oral administration 
and after 1 hour of IV administration.20,21 In the Phase III, 
double-blind, multicenter SECURE trial, 527 patients with IA 
or other filamentous fungi were randomized to receive either 
voriconazole or isavuconazole. There was low intra-subject 
variability and narrow trough-level distribution in the 
isavuconazole group, suggesting that routine TDM is not 
necessary.29,82 Terminal half-life elimination of isavucon-
azole ranges from 100 to 115 hours,20,21 and there is no clear 
exposure–response relationship,82 ie, low plasma levels did 
not clinically translate into a worse response. As a conse-
quence, isavuconazole TDM is not routinely recommended 
in the European Conference on Infectious in Leukemia 
(ECIL-6) guidelines30 and is only a CIII recommendation in 
the European Society of Clinical Microbiology and Infectious 
Diseases (ESCMID)/European Confederation of Medical 
Mycology (ECMM) 2018 guidelines.31 In contrast, TDM is an 
AI–AII recommendation for voriconazole (to ensure efficacy 
and avoid toxicity16) and posaconazole (to ensure efficacy18,32) 
when used for the treatment of invasive mold infections.
Table 1 Key pharmacokinetic characteristics of isavuconazole
Characteristics Isavuconazole
Dosage 200 mg q8h day 1+2; 
200 mg q24h maintenance
Resorption po/iv po = iv
Oral intake with/without food No influence
Half-life, hours 110–115
Oral bioavailability 98%
Linear pharmacokinetics Yes
Central nervous system penetration High (animal model)
Renal excretion ,1%
Metabolism CYP3A4/5
exposure–response relationship No
intra-patient variability Low
inter-patient variability Medium to low
Abbreviations: iv, intravenous; po, per oral; q8h, every 8 hours; q24h, every 
24 hours.
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Isavuconazole is thought to be widely distributed in 
nearly all tissues, including the liver, lungs, eyes, kidneys, 
bone, nasal mucosa, and brain. In rat animal models, mean 
plasma concentrations of isavuconazole were similar to 
mean brain concentrations after a single oral dose of isavu-
conazole (25 mg/kg).33 In 2 patients with fungal meningitis 
associated with contaminated epidural steroid injections 
who failed treatment with both liposomal amphotericin and 
voriconazole, salvage isavuconazole treatment led to com-
plete resolution of infection with negative follow-up cerebral 
spinal fluid (CSF) analysis at 1, 3, and 6 months posttreat-
ment. Both patients remained infection-free at 12 months 
following completion of therapy. This occurred despite low 
CSF levels of isavuconazole compared to plasma levels,34 
suggesting that the CSF levels may not adequately reflect the 
high brain tissue concentrations seen in animal studies.
Metabolism and elimination
There are negligible urinary concentrations of isavuconazole 
following oral administration with only slightly higher 
urinary concentrations following IV dosing.20,21 Thus, isa-
vuconazole dosage does not need to be reduced in patients 
with reduced renal function.28 Neither the area under the 
curve (AUC) nor the maximum serum concentration (C
max
) 
is affected in renal impairment, so no dose adjustment is 
recommended in individuals with mild, moderate, or severe 
renal impairment including end-stage renal disease (ESRD). 
Isavuconazole is not thought to be dialyzable.24 Metabolism 
of isavuconazole takes place in the liver by cytochrome P450 
(CYP) isoenzymes, particularly CYP3A4 and CYP3A5. 
Although patients with liver disease have higher exposure to 
isavuconazole, no dose adjustment is recommended in indi-
viduals with mild to moderate hepatic impairment (Child–
Pugh classes A and B). There are no data on individuals with 
severe liver disease (Child–Pugh class C).
Isavuconazole is a pregnancy class C drug and should not 
be given to pregnant women unless the potential benefit to the 
patient outweighs the risk to the fetus. The drug is excreted 
in the milk of lactating rats, and so it should be avoided in 
women who are breastfeeding.24
Pharmacodynamics
In vitro susceptibility profile of isavuconazole
Isavuconazole appears to be highly active against all Candida 
species including species such as C. glabrata and C. kru-
sei, which are inherently less susceptible to other azoles 
such as fluconazole.35,36 In one study of 296 isolates from 
bloodstream infections obtained over a period of 10 years, 
isavuconazole demonstrated greater potency than flucon-
azole against every organism tested and was as active as 
itraconazole and voriconazole.37 The minimum inhibitory 
concentration (MIC) values for 50% inhibitory (MIC
50
) 
and 90% inhibitory (MIC
90
) of all isolates were ,0.5 and 
,2.0 mg/L, respectively, for all major Candida species 
(Table 2). In another study of 1,358 isolates of Candida 
encompassing 11 different species, isavuconazole showed 
greater potency than posaconazole.38 Isavuconazole also 
has an excellent activity against Cryptococcus gattii and C. 
neoformans, with comparable efficacy to posaconazole and 
voriconazole and greater efficacy against some isolates with 
reduced fluconazole susceptibilities. This was demonstrated 
in a study of 128 cryptococcal isolates. The MIC
50
 and MIC
90
 
of 86 isolates of C. neoformans were ,0.015 and 0.6 mg/L, 
respectively, and those of 42 isolates of C. gattii were 0.03 
and 0.06 mg/L, respectively.39 Isavuconazole also has the 
activity against other yeast, including Trichosporon spp.40 
In addition, isavuconazole showed also the activity against 
Coccidioides (MICs: 0.06–0.12 µg/mL; n=6), Histoplasma 
(MICs: 0.03 µg/mL; n=2), and Paracoccidioides (MIC: 
0.001 µg/mL; n=1).87
Most importantly, isavuconazole has an outstanding 
activity against the most common species of Aspergillus. 
In a study of 118 isolates of Aspergillus spp., including A. 
fumigatus, A. terreus, A. flavus, and A. niger, isavuconazole 
demonstrated the activity against all four Aspergillus species 
including strains resistant to itraconazole, caspofungin, or 
amphotericin B.41,42 In addition, isavuconazole also dem-
onstrated the activity against A. lentulus.43 Importantly, 
isavuconazole has a very good activity against Mucorales,44 
although there is an unmet need of harmonization between 
methods that determine mucorales’s MICs and also Scedospo-
rium apiospermum but limited in vitro activity against Fusar-
ium species and Lomentospora prolificans (Table 3).45
Table 2 in vitro susceptibilities of isavuconazole against common 
medically important yeast
Organism MIC50 (mg/L) MIC90 (mg/L) References
Candida albicans 0.015 ,0.015–0.03 35–38, 40, 86
Candida glabrata ,0.015–0.5 0.2–2.0 35–38, 40, 86
Candida krusei ,0.015–0.5 ,0.015–1.0 35–38, 86
Candida parapsilosis ,0.015–0.06 0.023–0.12 35–38, 40, 86
Candida tropicalis ,0.015–0.06 ,0.015–0.5 35–38, 40, 86
Cryptococcus neoformans ,0.015–0.6 ,0.015–0.12 35, 36, 39
Cryptococcus gattii 0.03–0.06 0.06–0.125 38, 39, 43
Trichosporon spp. 0.06 0.5 40
Abbreviations: MiC50, minimum inhibitory concentration for 50% inhibitory; 
MiC90, minimum inhibitory concentration for 90% inhibitory.
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Safety and tolerability
Isavuconazole is thought to be safe and is generally well 
tolerated. In early single-ascending dose and multiple-dose 
studies, the most common reported side effects were upper 
respiratory symptoms, headache, and mild gastrointestinal 
symptoms including abdominal pain, nausea, and diarrhea.20,21 
Similar adverse events were found in a Phase II multicenter 
clinical trial of 160 participants with uncomplicated esopha-
geal candidiasis, in which subjects were randomized to three 
oral doses of isavuconazole or oral fluconazole. A minority of 
patients, 18.2%, experienced at least one medication-related 
adverse event, with anemia and gastrointestinal side effects 
including diarrhea and nausea being the most common.46 The 
SECURE trial found that although drug-related adverse events 
were common, there were significantly fewer adverse events in 
the isavuconazole group than in the voriconazole group (42% 
versus 60%, respectively).29 This was true in particular for eye 
disorders (number needed to treat [NNT] with isavuconazole=9 
to avoid the adverse event), skin and subcutaneous tissue 
disorders (NNT=11), and hepatobiliary disorders (NNT=14).29
In the early dosing trials, no serious adverse events were 
reported that were thought to be related to isavuconazole, 
although one study participant developed a mild elevation 
of liver transaminases leading to discontinuation of the 
study drug with subsequent normalization of liver function 
tests.20,21 In a Phase II trial, 2 patients in the isavuconazole 
arm experienced serious adverse events (atrioventricular 
block and tuberculosis pleurisy).46 There was a lower fre-
quency of drug-related hepatobiliary adverse events with 
isavuconazole compared to voriconazole (2% versus 10%, 
respectively) in the SECURE trial and fewer eye disorders 
in those that took isavuconazole compared to voriconazole 
(visual impairment, 4/257 [2%] versus 19/259 [7%], photo-
phobia, 2/257 [1%] versus 6/259 [2%], reduced visual acuity, 
1/257 [,1%] versus 6/259 [2%], and retinal hemorrhage, 
0/257 [0%] versus 5/259 [2%]). Furthermore, permanent 
drug discontinuation was lower for isavuconazole than for 
voriconazole (8% versus 14%, respectively).29 QT interval 
shortening can occur with isavuconazole, and this is thought 
to be dose-dependent, although there is no evidence of associ-
ated cardiac risk. Still, its use is contraindicated in patients 
with familial short QT syndrome (SQTS).47,48
Thus, isavuconazole seems to be at least as well toler-
ated as voriconazole and does not appear to be associated 
with some of the common side effects of voriconazole such 
as vision changes, photosensitivity, and hepatotoxicity. 
Although isavuconazole, like other azoles, has been associ-
ated with hepatotoxicity, this is generally reversible and 
generally does not require drug discontinuation.24 Infusion 
reactions including hypotension, dyspnea, chills, dizziness, 
and paresthesias have been reported during infusion and may 
require discontinuation of the infusion.24 Following dilution, 
IV isavuconazole may form precipitate from the insoluble 
isavuconazole, so it is recommended that isavuconazole 
should be administered through an in-line filter.24
Drug–drug interactions
Isavuconazole is a sensitive substrate of CYP3A4, so medi-
cations that inhibit this enzyme can increase isavuconazole 
levels and should be used cautiously if used concurrently. 
Isavuconazole use with strong CYP3A4 inhibitors such 
as ketoconazole and high-dose ritonavir as well as strong 
CYP3A4 inducers such as long-acting barbiturates, St John’s 
wort (Hypericum perforatum), carbamazepine, and rifampin 
is contraindicated. Isavuconazole is a moderate inhibitor 
of CYP3A4 and can increase drug levels of atorvastatin, 
cyclosporine, sirolimus, tacrolimus, midazolam, and myco-
phenolate mofetil; concurrent use of these drugs should be 
closely monitored. Although studies have shown that isa-
vuconazole may be favorable because of limited drug–drug 
interactions compared to other second-generation azoles 
when used together with these immunosuppressants, drug 
levels of cyclosporine, sirolimus, and tacrolimus, if used 
concurrently with isavuconazole, should be monitored and 
if necessary adapted.49 Isavuconazole is a mild inhibitor of 
P-glycoprotein (P-gp), so when used with digoxin, serum 
digoxin levels should be routinely monitored.24 Given the 
potential for isavuconazole to shorten the QTc interval, it 
should be prescribed with caution when prescribed with 
medications known to shorten the QTc interval.47,48
Efficacy against aspergillosis
IA is the most frequently encountered invasive mold infec-
tion in immunocompromised patients, with mortality rates 
of 30%–40%.6,7,50
Table 3 in vitro susceptibilities of isavuconazole against medically 
important molds 
Organism MIC50 (mg/L) MIC90 (mg/L) References
Aspergillus fumigatus 0.25–1.0 0.5–2.0 36, 42, 45
Aspergillus terreus 0.38–0.5 0.5 42, 45
Aspergillus flavus 0.38–2.0 0.5–2.0 36, 42, 44, 45
Aspergillus niger 0.5 0.75–2.0 42, 45
Fusarium spp. 8.0–.32 .8.0–.32 44
Scedosporium 
apiospermum
.32 .32 45
Mucor spp. 2 .32 44, 45
Rhizopus spp. 1 .32 44, 45
Abbreviations: MiC50, minimum inhibitory concentration for 50% inhibitory; 
MiC90, minimum inhibitory concentration for 90% inhibitory.
Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1037
isavuconazole for the treatment of iA and mucormycosis
In vivo antifungal susceptibility profiles 
based on animal models
Preclinical studies exploring the efficacy of isavuconazole 
for IA treatment investigated several animal models with 
A. fumigatus, A. flavus, and A. terreus infections, with a 
particular focus of A. fumigatus in invasive pulmonary asper-
gillosis models. Petraitis et al51 investigated several dosing 
regimens of isavuconazole in severely neutropenic rabbits,52 
who were infected with the NIH4215 A. fumigatus strain via 
endotracheal inoculation. Following infection, these rabbits 
received an oral loading dose of isavuconazole (90 mg/kg) 
followed by oral isavuconazole (20, 40, or 60 mg/kg once 
daily). Rabbits treated with voriconazole (15 mg/kg orally 
twice daily) and untreated rabbits were used as control 
groups. Results showed an improved survival in all the three 
isavuconazole groups compared to untreated rabbits, as well 
as an improved survival in rabbits treated with isavuconazole 
(40 mg/kg [six of nine surviving] and 60 mg/kg [four of nine 
surviving]) compared to rabbits in the voriconazole group 
(zero of eight surviving). In addition, compared to the control 
and voriconazole groups, rabbits in the isavuconazole groups 
showed reduced fungal burdens in lung tissue as well as lower 
serum and bronchoalveolar lavage fluid galactomannan levels 
and serum 1,3-β-d-glucan levels. A similar model compared 
the activity of isavuconazole in mice infected with a different 
A. fumigatus strain (AF293).52 In this study, mice were treated 
with either subcutaneous isavuconazole (15 and 30 mg/kg 
twice daily) or oral posaconazole with a control group of 
untreated mice. While posaconazole improved survival 
and decreased fungal lung burden, isavuconazole neither 
improved survival nor reduced fungal burden in lung tissue, 
compared to untreated mice. Notably, in this study, isavu-
conazole concentrations in lung tissue were low (,1 µg/mL), 
possibly due to subcutaneous administration or due to a higher 
MIC of the A. fumigatus strain. Furthermore, the combina-
tion of a lower AUC of isavuconazole and higher MIC may 
have resulted in a lower AUC/MIC ratio, which is a strong 
predictor for treatment efficacy in animal studies.53,54
Isavuconazole activity was also investigated against 
A. flavus in mice models.42 In this study, mice were treated 
with cyclophosphamide to induce a neutropenic state and 
were infected intravenously with A. flavus (strain AFL8). 
Different doses of isavuconazole were compared to voricon-
azole, itraconazole, and caspofungin. Dosing of antifungals 
was done 2 hours pre-infection, 4 hours post-infection, or 
24 hours post-infection as follows: oral isavuconazole (3, 
6, or 15 mg/kg) three times daily at day 1 and day 2 fol-
lowed by twice daily dosing; oral voriconazole (10 mg/kg) 
once daily; oral itraconazole (10 mg/kg) three times daily 
on day 1 and day 2 followed by twice daily dosing; and IV 
caspofungin (1 mg/kg) once daily. End points were survival 
after 14 days of infection and fungal tissue burden (kidneys, 
liver, lungs, brain, and spleen) obtained by fungal culture and 
quantitative real-time polymerase chain reaction (PCR). In 
the pre-infection cohorts dosed with isavuconazole (6 mg/
kg) and caspofungin, there was a 100% survival rate at day 
14 versus a 0% survival rate at day 14 in the voriconazole 
cohort. In the 4-hour post-infection cohorts dosed with isa-
vuconazole (15 mg/kg), voriconazole, and caspofungin, there 
was an 83% survival rate (five out of six animals survived). 
In the 24-hour post-infection groups dosed with isavucon-
azole (15 and 30 mg/kg) and caspofungin, there was a 100% 
survival rate.42
In a similar study investigating mice with disseminated 
aspergillosis infected with A. fumigatus, A. flavus, or 
A. terreus, various doses of isavuconazole were compared to 
amphotericin B, caspofungin, voriconazole, and an untreated 
control group. The primary end point was fungal clearance. 
Isavuconazole and comparator antifungals were found to 
be similarly efficacious in clearing fungal burden from the 
kidneys of mice infected with Aspergillus spp., including the 
A. flavus strain and the A. terreus strain (AT49), showing a 
high minimal fungicidal concentration.54
Clinical efficacy of isavuconazole against IA
After showing in vitro activity against Aspergillus, isavu-
conazole entered clinical studies (Phase II and Phase III). 
Safety, efficacy, and dosing regimens of isavuconazole 
were investigated in two Phase II studies.46,55 Based on these 
results, a Phase III, double-blind, randomized, non-inferiority 
trial was performed comparing the efficacy and safety of 
isavuconazole versus voriconazole as primary treatment of 
invasive fungal diseases caused by Aspergillus spp. or other 
filamentous molds (SECURE trial).29 The primary end point 
of this study was all-cause mortality at day 42 of treatment 
in intention-to-treat (ITT) analysis. Secondary end points 
included overall treatment response at the end of treatment; 
all-cause mortality at day 84 of treatment; a composite of 
clinical, mycological, and radiological responses; and safety 
and tolerability profiles. A total of 527 patients were random-
ized to receive either isavuconazole (n=263) at a dose of 
200 mg intravenously three times daily on day 1 and day 2, 
followed by 200 mg orally or intravenously once daily, or 
voriconazole (n=264) at doses of 6 mg/kg twice daily intra-
venously on day 1 and 4 mg/kg intravenously twice daily on 
day 2, followed by either IV treatment with 4 mg/kg twice 
daily or 200 mg orally twice daily. A total of 516 patients 
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(256 per group) received at least one dose of isavuconazole 
or voriconazole. Out of the 516 patients, a data-reviewing 
committee identified 272 patients as having proven or prob-
able invasive mold disease (modified ITT [mITT] popula-
tion) and 231 as having proven or probable IA (mycological 
ITT [myITT] population). Aspergillus spp. were identified 
as the primary pathogen in ~30% of the mITT population, 
with A. fumigatus being the most common pathogen. Mixed 
mold infections were observed in 2% of the mITT population.
Regarding the primary end point of all-cause mortality 
at day 42, isavuconazole was found to be non-inferior to 
voriconazole in the ITT population (19% mortality in the 
isavuconazole group versus 20% in the voriconazole group; 
adjusted treatment difference -1.0%, 95% confidence inter-
val: -7.8% to 5.7%). Results were similar for the mITT 
and myITT populations (20% versus 23% and 19% versus 
22%, respectively). Overall treatment response at the end 
of treatment – including clinical, mycological, and radio-
logical responses – and mortality at day 84 were similar 
in both groups. However, patients receiving isavuconazole 
developed significantly fewer hepatobiliary, eye, and skin 
disorders. In addition, treatment discontinuation due to drug-
related events was significantly lower in the isavuconazole 
group. Thus, the SECURE study showed isavuconazole to 
be non-inferior to voriconazole for the treatment of invasive 
mold diseases due to Aspergillus spp. or other filamentous 
fungi, with a lower rate of adverse events. Based on this 
study, the European Medicines Agency (EMA) and the US 
Food and Drug Administration (FDA) licensed isavuconazole 
for the treatment of IA.
Guideline recommendations
Both isavuconazole and voriconazole are recommended 
as first-line treatment for IA in patients with hematologi-
cal malignancies in the ESCMID/ECMM 2018 guidelines 
(AI recommendation)31 and the ECIL-6 guidelines (AI–AII 
recommendation)30 (Table 4). This contrasts to liposomal 
amphotericin B, which has BI and BII recommendations 
in both European guidelines. The 2016 Infectious Diseases 
Society of America (IDSA) guidelines differ slightly from the 
European guidelines, giving voriconazole an AI recommen-
dation and both isavuconazole and liposomal amphotericin B 
an AII recommendation.56 Given the favorable safety profile 
of isavuconazole compared to voriconazole, isavuconazole 
may become the treatment of choice for IA in patients with 
hematological malignancies.
Given a lack of data for the treatment of IA with isavu-
conazole in patients without hematological malignancies, 
voriconazole remains the sole first-line treatment option 
in this context (voriconazole has an AIII recommendation 
in the ESCMID 2018 guidelines).31 There are also limited 
data on isavuconazole as salvage treatment in patients with 
and without hematological malignancies, so posaconazole, 
liposomal amphotericin B, and voriconazole remain the 
antifungal agents of choice in these settings.30,31 Limited 
data exist on the efficacy of isavuconazole for the treatment 
of chronic pulmonary aspergillosis (CPA). However, given 
the low MICs of Aspergillus spp. and the favorable safety 
profile of isavuconazole, it has been recommended as a 
third-line treatment for CPA in those that failed treatment 
with voriconazole and itraconazole.54
Isavuconazole: efficacy against 
mucormycosis
Mucormycosis is a rare but life-threatening disease that is 
caused by various species of the order Mucorales. The infec-
tion not only occurs primarily in patients with hematological 
malignancies, including patients following hematopoietic 
stem cell transplantation, but also occurs in other immuno-
compromised patients including those with iron overload 
and diabetes mellitus.57
If not promptly diagnosed and treated, mucormycosis is 
associated with .90% mortality.57 Preventing such outcomes 
requires appropriate clinical awareness and a high index of 
suspicion since current diagnostic modalities have limited 
reliability and are often invasive. Positive clinical outcomes 
require early antifungal administration and may require 
extensive surgery.
Until the approval of isavuconazole, liposomal formu-
lation of amphotericin B (lipAmB) has been the first-line 
antifungal treatment of mucormycosis, whereas posaconazole 
has been recommended for lipAmB intolerant or refractory 
cases.58,59 The addition of surgical debridement and, if pos-
sible, the correction of the underlying immunosuppression 
and control of diabetes have led to a 40% reduction in 
Table 4 Guideline recommendations for the treatment of invasive 
(pulmonary) aspergillosis in hematological malignancy patients
Guideline Isavuconazole Voriconazole Liposomal 
amphotericin B
eCiL-630 Ai Ai Bi
eSCMiD/
eCMM 201831 
Ai–Aii Ai–Aii Bii
iDSA 201656 Aii Ai Aii
Abbreviations: eCiL-6, european Conference on infectious in Leukemia; eCMM, 
european Confederation of Medical Mycology; eSCMiD, european Society of 
Clinical Microbiology and infectious Diseases; iDSA, infectious Diseases Society of 
America.
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mortality over the past decade.58 However, the use of anti-
fungals is often restricted given the common adverse effects 
of lipAmB, which often cannot be used in patients with renal 
impairment, and a lack of data supporting first-line treatment 
with posaconazole.
Given the low prevalence and wide clinical and micro-
biological spectrum of infections caused by mucormycetes, 
recommendations for the treatment of these infections had 
been mostly based on registry data, small prospective non-
controlled studies, and small retrospective trials.59 In the 
Deferasirox-AmBisome Therapy for Mucormycosis study, 
20 patients suffering from mucormycosis were random-
ized to receive lipAmB combined with deferasirox, an iron 
chelating agent, or lipAmB and placebo. Patients treated with 
adjunctive deferasirox had increased mortality, and the trial 
was discontinued.60 In the AmBizygo study, a single-arm 
Phase II trial, 34 patients were treated with 10 mg/kg per day 
of lipAmB for disseminated mucormycosis. The mortality 
rate at 12 weeks was 38%, but 40% of patients developed 
significant nephrotoxicity.61
Isavuconazole has shown convincing in vitro and pre-
clinical in vivo data – including linear pharmacokinetics 
and high bioavailability – and good activity against a wide 
spectrum of fungal pathogens including mucormycetes.62–64 
In addition, isavuconazole was well tolerated by healthy 
volunteers as well as patients undergoing chemotherapy for 
acute leukemia in Phase II studies. The VITAL Phase III 
study was a single-arm open-label study of isavuconazole for 
the treatment of disseminated mucormycosis, combined with 
a case–control analysis comparing matched cases treated with 
lipAmB from the Fungiscope registry65 and assessed the safety 
and efficacy of isavuconazole for the treatment of infections 
caused by mucormycetes and other rare molds. The primary 
objective was to assess the efficacy of isavuconazole, and 
the case–control analysis evaluated the mortality outcomes 
in patients who took isavuconazole compared to lipAmB.66 
Adult patients ($18 years) were recruited from 34 centers 
worldwide from April 2008 to June 2013. The study defined 
primary treatment of mucormycosis as #4 days of previous 
systemic antifungal therapy. Patients were eligible if they 
had been refractory or intolerant to other antifungal drugs. 
Disseminated mucormycosis was defined as involving .1 
noncontiguous body region. The diagnostic certainty of 
invasive fungal disease using European Organization for 
Research and Treatment of Cancer/Mycoses Study Group 
criteria was evaluated by an independent data review com-
mittee, and mucormycosis infection was defined as “proven” 
if there was histopathological evidence of disease or growth 
on culture from sterile body sites or defined as “probable” 
in the case of pathogen growth from respiratory specimens 
in patients with lung infiltrates and/or pneumonia and no 
alternative etiology for infection. Participants received an 
IV or oral loading dose of isavuconazole (200 mg), every 
8 hours for six doses, followed by isavuconazole (200 mg 
daily). At day 42, day 84, and at the end of treatment, the 
investigators assessed and documented clinical, radiological, 
and mycological responses.
To assess the clinical efficacy of isavuconazole for the 
treatment of mucormycosis, the investigators performed a 
matched case–control analysis using data from the Fungi-
Scope registry, which is a global, anonymized database of 
rare invasive fungal diseases. In this matched case–control 
analysis, patients receiving primary treatment with isavu-
conazole were matched with FungiScope patients who had 
been treated with first-line therapy with amphotericin B. 
The primary study end point was defined as overall response 
at day 42. Secondary end points included all-cause mortality 
rates at day 42 and day 84, and clinical, radiological, and 
mycological responses at day 42, day 84, and at the end 
of treatment.
Of the 149 patients with invasive fungal infections (IFIs) 
enrolled, 37 had proven (86%) or probable (14%) mucormy-
cosis. Twenty-one patients were treated with isavuconazole 
first-line, 11 for refractory disease, and 5 after intolerance to 
other antifungals. By treatment day 84, complete response 
was documented in 2 (5%) of 37 patients, partial responses 
in 5 patients (14%), and stable disease in 11 patients (30%). 
All-cause mortality was 43% (16 of 37 patients).
The reasons for discontinuation of isavuconazole 
treatment were death (11 patients [30%]), adverse events 
(6 patients [16%]), noncompliance (4 patients [11%]), 
treatment response failure (2 patients [5%]), and deci-
sion of an investigator (1 patient [3%]). Adverse events 
that led to cessation of treatment were relapse or pro-
gression of malignant disease (2 patients), liver injury 
(2 patients), Gram-negative bacteremia (1 patient), and 
nausea (1 patient). The adverse events reported by .10% 
of patients were similar to those reported in the SECURE 
trial, mostly gastrointestinal symptoms (nausea, vomiting, 
and diarrhea).
In the matched case–control analysis, 33 patients treated 
with amphotericin B in the FungiScope registry were matched 
as controls to 21 VITAL study patients who received isavu-
conazole for primary antifungal treatment. Survival prob-
ability through day 84 was similar between FungiScope 
control cases (50%) and VITAL study patients (57%). 
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A correlation between fungal isolate MICs, isavuconazole 
plasma concentrations, and key outcomes could not be 
identified.
Apart from the VITAL study, isavuconazole has been 
reported as a successful salvage therapy for mucormycosis 
in single case reports.67–70
Guideline recommendations
In summary, the VITAL study showed that isavuconazole 
was efficacious for both primary and salvage therapies 
(refractory or intolerant to other antifungals) for the treat-
ment of mucormycosis infections, with overall end-of-
treatment complete and partial responses of 32% for primary 
treatment and 36% for the treatment of mucormycosis 
refractory to other antifungals. These findings were similar to 
response rates reported for lipAmB, although isavuconazole 
lacks the dose-limiting nephrotoxicity of lipAmB. Overall, 
isavuconazole was well tolerated and safe, and toxicity was 
an uncommon cause for treatment discontinuation. Based 
on these results, the FDA has licensed isavuconazole for the 
treatment of mucormycosis infections, whereas the EMA 
has licensed isavuconazole for use in cases where AmB 
cannot be used, so AmB formulations likely continue to be 
the first-line treatment for mucormycosis in Europe. Still, 
isavuconazole and posaconazole may be viable options to 
AmB in patients who do not tolerate liposomal amphotericin 
B and those with reduced renal function. Updated guidelines 
are needed that define the role of isavuconazole for the treat-
ment of mucormycosis.
Real-life data
Clinical decisions should be based on the guideline recom-
mendations that reflect an expert consensus based on available 
evidence. However, in real-world scenarios, the choice of an 
appropriate antifungal agent may be complicated by several 
factors including serious drug allergies such as anaphylaxis, 
fungal resistance, nephrotoxicity, drug–drug interactions, and 
the need for a reliable oral formulation, as demonstrated in 
a recently published case report.10 Thus, isavuconazole may 
find greater use despite the aforementioned recommenda-
tions. Although voriconazole remains the treatment of choice 
for central nervous system (CNS) aspergillosis due to its 
superior penetration into the CNS,71,72 isavuconazole may be 
the best second-line alternative, despite the limited amount 
of data that are available on isavuconazole efficacy in cases 
of CNS infection.
Data on the use of isavuconazole as antifungal prophy-
laxis are very limited. In the recently published 2017 update 
of the recommendations of the Infectious Diseases Working 
Party (AGIHO) of the German Society for Haematology and 
Medical Oncology (DGHO), isavuconazole was graded as 
CII in patients with neutropenia (,500 cells/µL .7 days), 
a lower grade than other antifungal drugs due to limited data 
supporting its use as prophylaxis.73 Clinical studies investi-
gating prophylaxis with isavuconazole in patients undergoing 
allogeneic hematopoietic stem cell transplant (ClinicalTrials.
gov identifier: NCT03149055) and in patients with acute 
myeloid leukemia (AML) or myelodysplastic syndrome and 
neutropenia (ClinicalTrials.gov identifier: NCT03019939) 
are currently recruiting patients.
A small Phase II dose escalation study supports the 
safety and tolerability of IV isavuconazole prophylaxis in 
patients with AML who had undergone chemotherapy and 
had preexisting/expected neutropenia.55 After a loading dose, 
maintenance isavuconazole was administered at 200 mg 
(low-dose cohort) and 400 mg (high-dose cohort) once daily 
for 23 days. Eighteen of 20 patients who completed the study 
were classified as a treatment success, whereas 2 patients in 
the low-dose cohort developed possible IFI. Four patients 
discontinued the study due to adverse events (two in each 
cohort), but no drug-related treatment-emergent adverse 
event was considered as life threatening. Most adverse events 
were classified as mild to moderate in severity including 
headache and rash (55% high-dose cohort versus 25% low-
dose cohort). Cardiac QTc prolongation under isavuconazole 
treatment was not observed during this study.
Unlike other azoles which can result in QTc interval 
prolongation, QTc interval shortening has been reported 
with isavuconazole. In a large Phase I, randomized, double-
blind study, healthy individuals who received isavuconazole 
(n=69) developed a shortened QTc interval, which was both 
dose and plasma concentration dependent.47 There was no 
association with cardiovascular events based on a post hoc 
analysis of the Phase III SECURE trial.29,47 This was recently 
confirmed by a smaller study reporting that 24 out of 26 
patients treated with isavuconazole developed a shortened QTc 
interval with a mean decrease of 36.5±38.8 ms (7.4%±5.8%) 
compared to the pre-isavuconazole electrocardiogram.48
Thus, isavuconazole should be considered for use over 
the other azoles in patients on medications that have a 
known risk of QTc interval prolongation. Furthermore, isa-
vuconazole could be an alternative in patients who develop 
azole-induced QTc interval prolongation. This approach has 
been reported in a recent case report of a 22-year-old woman 
with cystic fibrosis who developed voriconazole-associated 
QTc prolongation up to 613 ms in the absence of any 
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electrolyte abnormality. Change from voriconazole to 
isavuconazole leads to a decrease in the QTc interval to 
468 ms after 24 hours.74 However, patients with a known 
familial SQTS, which is a rare autosomal dominant inherited 
channelopathy, should not receive isavuconazole. In addi-
tion, isavuconazole can also be considered as an alternative 
antifungal treatment to other azole-induced adverse events 
including severe allergic reactions.75 Single case reports 
recommend a graded drug challenge with isavuconazole in 
case of previous azole-associated allergy.75,76
Based on a Phase I study, dose adjustment of isavucon-
azole is not required in patients with renal impairment or 
in patients who receive hemodialysis.77 Pharmacokinetic 
parameters were similar between healthy individuals and 
patients with mild, moderate, and severe renal impairment 
without a significant impact on renal function. In case of 
ESRD, isavuconazole can be administered before hemodi-
alysis as isavuconazole is highly protein-bound (.98% to 
albumin) and unlikely to be cleared during hemodialysis. 
Conversely, hemodialysis cannot be used to clear isavucon-
azole in case of overdoses, whereas plasmapheresis may be 
a feasible option.
Current evidence suggests that for patients with IA or 
mucormycosis and mild to moderate hepatic impairment 
due to alcoholic cirrhosis or hepatitis B/C virus infection, 
no dose adjustment of isavuconazole is needed.78 Initially, 
dose adjustment of isavuconazole was recommended in 
patients with liver disease as data indicated that isavucon-
azole, which is primarily eliminated by hepatic metabolism, 
leads to a decreased systemic clearance after IV or oral 
administration and an increased half-life of isavuconazole 
in patients with mild and moderate liver impairment, 
compared to healthy individuals.79 However, based on a 
population pharmacokinetic model using data from this 
study, the authors revoked the recommendation later.78,79 
Pharmacokinetic data in patients with severe hepatic 
impairment classified as Child–Pugh C are lacking. Dose 
adjustment is not necessary when changing from IV to oral 
formulations because oral isavuconazole is bioequivalent 
to the IV formulation.27
Based on EUCAST clinical breakpoints, isavucon-
azole is classified as susceptible in isolates with an MIC 
of #1 mg/L.80 Recently published data indicate that high-
dose isavuconazole treatment (eg, 400 mg once daily) might 
be an option in carefully selected patients infected with an 
A. fumigatus isolate with an isavuconazole MIC of 2 mg/L.81 
However, this study also showed that isavuconazole cannot 
be used for the treatment of patients with IA caused by an 
A. fumigatus strain with TR34/L98H and TR46/Y121F/
T289A azole resistance mutations.
TDM may be considered in selected patients, especially 
when using high-dose isavuconazole treatment, but current 
clinical evidence does not recommend routine TDM for 
isavuconazole.82 Recently published data showed that the 
clinical dosing regimen achieved exposures adequate to treat 
IA in post hoc analyses of plasma isavuconazole concentra-
tions of patients from the SECURE clinical trial.29,82
When compared to voriconazole, isavuconazole has been 
reported to be cost-effective for the first-line treatment of 
IA.83 Economic modeling assessed a cost saving of 7,418 
US dollars per patient for isavuconazole compared to vori-
conazole. Astellas Pharma Global Development, Inc. funded 
this study. Evaluation was from a US hospital perspective 
using clinical data from the SECURE trial, including length 
of stay for the initial admission, incidence of readmission, 
clinical response, overall survival rates, and experience of 
adverse events.
Conclusion and place in therapy
Isavuconazole is a new second-generation triazole with a 
broad-spectrum antifungal activity and a favorable pharma-
cokinetic and safety profile, not requiring TDM. Compared 
to voriconazole and liposomal amphotericin B, it offers 
some advantages including good tolerability, a lower side 
effect profile,29 excellent bioavailability (switch from IV to 
oral treatment),27 and reduced drug–drug interactions.49,84,85 
In the Phase III SECURE trial, isavuconazole demonstrated 
similar efficacy to voriconazole for the treatment of IA.29 
Recent guidelines recommend isavuconazole as gold stan-
dard treatment (together with voriconazole) for IA in patients 
with hematological malignancies.30,31 In addition, isavucon-
azole has shown similar efficacy to liposomal amphotericin 
B for the treatment of infections from mucormycosis66 and 
is frequently used in real-life settings for the treatment of 
mucormycosis in patients who cannot tolerate liposomal 
amphotericin B (eg, reduced renal function). Updated 
guidelines on mucormycosis are needed to reflect the current 
evidence and give guidance on the use of isavuconazole for 
mucormycosis. Importantly, for empiric antifungal treatment, 
and treatment of suspected mold infections with unknown 
causative pathogen, isavuconazole and posaconazole may 
have favorable outcomes compared to voriconazole given 
their efficacy against mucorales.
Studies are needed to evaluate the role of isavuconazole 
for 1) anti-mold prophylaxis in high-risk patients; 2) treatment 
of IA in intensive care/solid-organ transplant/pulmonology 
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settings, ie, in patients at risk but without an underlying 
hematological malignancy; 3) salvage treatment for IA and 
mucormycosis; and 4) treatment for other mold infections 
such as S. apiospermum.
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